Strong T-cell response for blood cancer patients after vaccine; COVID breakthrough often serious for cancer patients

The following is a summary of some recent studies on COVID-19 and cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Blood cancer patients show strong T-cell response to COVID vaccines. Patients with blood cancers have a significantly weaker antibody response to COVID-19 vaccines than patients with solid tumors, but they may still be well protected against severe illness from the virus, new data suggests.